Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
Authors' conclusion
Chronic therapy with GLP-1 RA and/or SGLT-2i has a favorable impact on the clinical outcome of DM patients hospitalized with AMI.
Study context
- Population
- Patients hospitalized with acute myocardial infarction (AMI) in Lombardy, 2010–2019 (mean age 71 ± 13 years, 34% females, 47% STEMI; 26% with diabetes mellitus (DM))matched
- Participants
- 3,090 patients
- Exposure
- DM on GLP-1 RA and/or SGLT-2i vs DM not treated vs non-DM
- Non-DMn = 1,030reference
- DM with GLP-1 RA/SGLT-2in = 1,030
- DM without GLP-1 RA/SGLT-2in = 1,030
- Outcome
- Composite of:
- In-hospital mortality
- Acute HF
- Acute kidney injury requiring renal replacement therapy
- Follow-up
- In-hospital
Methodological detailspropensity score matching, health administrative databases of Lombardy
- Propensity score matching
- Health administrative databases of Lombardy
Main finding
As reported in the abstract
Primary composite endpoint
Higher risk
30%
DM with GLP-1 RA/SGLT-2i
Higher risk
60%
P < 0.0001
DM without GLP-1 RA/SGLT-2i
- Overall primary endpoint rate
- 16% (n = 502)
- Progressive increase across the three groups
- P < 0.0001
Observational data: associations, not effects.
Original publication
Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction. Cardiovasc Diabetol. Published 6 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →